V+M AKTUELL - Apeptico GmbH: The patent “Prevention and Treatment of Hyperpermeability” ranks among the 10 most innovative inventions of the year 2011 in Austria

The patent “Prevention and Treatment of Hyperpermeability” ranks among the 10 most innovative inventions of the year 2011 in Austria

Vienna, Austria, 26th January, 2012- The patent “Prevention and Treatment of Hyperpermeability” invented and owned by APEPTICO GmbH ranks among the 10 most innovative inventions of the year 2011 in Austria. Today, APEPTICO’s patent AT_507_953 was awarded the INVENTUM nomination based on a decision of a jury composed of patent experts of the Austrian Patent Office and the Federal Ministry for Transport, Innovation and Technology.

The patent “Prevention and Treatment of Hyperpermeability” of APEPTICO Forschung und Entwicklung GmbH describes the circularised peptide “AP301” and its use for prophylactic and therapeutic treatment of damaged lung tissue. Injury of the barrier function of the pulmonary endothelial-epithelial cell layer leads to infiltration of blood and blood components into the airspace and formation of a pulmonary oedema. Fluid in the lung then strongly prevents normal gas exchange in the lung and such patients suffer from the life-threatening condition “Acute Lung Injury”. Currently, no specific drug treatment exists for patients suffering from hyperpermeability-caused lung oedema. Currently, APEPTICO’s peptide AP301 is subject to clinical studies.

About APEPTICO GmbH

APEPTICO Forschung und Entwicklung GmbH is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids any risk of transmitting microbial and viral infections. Development cost and time to market are significantly reduced if compared to the recombinant development process of biomolecules. APEPTICO’s development platform PEPBASETM combines structural, functional and clinical data from relevant biopharmaceuticals and well-characterised proteins. Based on preclinical and clinical data, including adverse reactions, risk factors and contraindications to be circumvented and supported by structural, biochemical and physicochemical data, for each relevant protein a specific profile is established that links biological & functional properties with discrete structural elements.

Link

www.apeptico.com

Contact

Univ.- Doz. Dr. Bernhard Fischer
Chief Executive Officer

APEPTICO Forschung und Entwicklung GmbH
Mariahilferstraße 136
A-1150 Vienna, Austria
T: +43-664-1432919
b.fischer@apeptico.com
www.apeptico.com

	V+ Management GmbH
	V+M AKTUELL - AK-2012-04-03 - Cologne 26.01.2012
	The patent “Prevention and Treatment of Hyperpermeability” ranks among the 10 most innovative inventions of the year 2011 in Austria Vienna, Austria, 26th January, 2012- The patent “Prevention and Treatment of Hyperpermeability” invented and owned by APEPTICO GmbH ranks among the 10 most innovative inventions of the year 2011 in Austria. Today, APEPTICO’s patent AT_507_953 was awarded the INVENTUM nomination based on a decision of a jury composed of patent experts of the Austrian Patent Office and the Federal Ministry for Transport, Innovation and Technology. The patent “Prevention and Treatment of Hyperpermeability” of APEPTICO Forschung und Entwicklung GmbH describes the circularised peptide “AP301” and its use for prophylactic and therapeutic treatment of damaged lung tissue. Injury of the barrier function of the pulmonary endothelial-epithelial cell layer leads to infiltration of blood and blood components into the airspace and formation of a pulmonary oedema. Fluid in the lung then strongly prevents normal gas exchange in the lung and such patients suffer from the life-threatening condition “Acute Lung Injury”. Currently, no specific drug treatment exists for patients suffering from hyperpermeability-caused lung oedema. Currently, APEPTICO’s peptide AP301 is subject to clinical studies. About APEPTICO GmbH APEPTICO Forschung und Entwicklung GmbH is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids any risk of transmitting microbial and viral infections. Development cost and time to market are significantly reduced if compared to the recombinant development process of biomolecules. APEPTICO’s development platform PEPBASETM combines structural, functional and clinical data from relevant biopharmaceuticals and well-characterised proteins. Based on preclinical and clinical data, including adverse reactions, risk factors and contraindications to be circumvented and supported by structural, biochemical and physicochemical data, for each relevant protein a specific profile is established that links biological & functional properties with discrete structural elements. Link www.apeptico.com Contact Univ.- Doz. Dr. Bernhard Fischer Chief Executive Officer APEPTICO Forschung und Entwicklung GmbH Mariahilferstraße 136 A-1150 Vienna, Austria T: +43-664-1432919 b.fischer@apeptico.com www.apeptico.com
	Contact Venture Capital V+ Management GmbH Wupperplatz 7 D-51061 Köln CEO Michael Vogel Fax +49 (0)221 96 49 02 18 vogel[a]vplus-management.de www.vplus-management.de Michael Vogel, CEO of V+ Management GmbH in Cologne, began his successful career in venture capital/private equity in 2002. He then specialised in venture capital at the Munich University of Applied Sciences in 2005-06, and this expertise has enabled him to make venture capital investments in numerous companies to date through three funds. V+ GmbH & Co. Fonds 3 KG builds on the sound track record of the previous V+ investment funds, supported by public auditor Uwe Kerner from Dresden, the advisory boards and a number of partners. Private investors should be able to invest in the German economy for their own benefit and in so doing create a solid foundation for ideas and innovation. In line with the V+ philosophy of “using money meaningfully”, V+ GmbH & Co. Fonds 3 KG places investors’ funds in direct holdings exclusively in compliance with the V+ETHICAL INDEX. In accordance with this index, V+ seeks companies that offer products or technologies with a competitive edge or a unique selling proposition. Most target companies are based in Germany, Austria or Switzerland. The companies should demonstrate an overarching commitment to providing responsible products and services which offer long-term benefits for the world and clear advantages for the people in our society. Legal Notice Although all links to third-party websites have been carefully checked, we assume no responsibility for the content of these websites. The operators of these websites bear sole responsibility for their content.